What we do

Invicol is a specialized medical technology company focused on the development and production of a medical device.

The minimal invasive approach

Invicol GmbH is a biotech start-up located in the CoLaborator of the Bayer AG in Berlin, where we are developing the BMProbe – a medical device that is inserted into the patients cubital vein for the isolation of rare circulating cells. The minimal invasive approach has a high sensitivity and specificity providing compelling and improved diagnostic value. Our technology opens new possibilities in the field of personalized medicine, early diagnosis and disease monitoring. 

The <strong>minimal invasive</strong> approach

Projects

Development of an innovative medical device for in vivo isolation of Circulating Endothelial Cells

The aim of this project is an optimization of the BMProbes’ geometry and the validation of its functionality. An optimized geometry increases the blood volume that is screened by the BMProbe during its application. This joint project will be cofinanced within the framework by the IBB Pro Fit and European Regional Development Fund.

Funding Program: Pro FIT Projektfinanzierung
Funded by: EFRE
Project duration: 01.07.2018 – 31.12.2020
Cooperation partners: Beuth Hochschule für Technik und Charité – Universitätsmedizin Berlin

Development of an innovative medical device for <i>in vivo</i> isolation of <strong>Circulating Endothelial Cells</strong>

Development of an innovative medical device for in vivo isolation of Circulation Tumor Cells

The aim of this project is the development for an in vivo approach to isolate CTCs from the peripheral blood stream. The main claim is to enrich sufficiently CTCs onto the BMProbe for a successful diagnostic tool.

This joint project will be cofinanced within the framework by the IBB Pro Fit and European Regional Development Fund. Together with the Biofluid Mechanics Lab of the Charité Berlin and the University of Potsdam.

Funding Program: Pro FIT Projektfinanzierung
Funding by: EFRE
Project duration: 01.01.2020 – 30.10.2022
Cooperation partner: Charité – Universitätsmedizin Berlin and University of Potsdam

Development of an innovative medical device for <i>in vivo</i> isolation of <strong>Circulation Tumor Cells</strong>

Introducing the BMProbe

In contrast to many available products that are based on in vitro methodology the BMProbe isolates cells in vivo. The BMProbe is inserted into the patients’ cubital vein through a catheter or indwelling line. This means that in most cases, no additional punctuation is necessary.

The geometry of the BMProbe was optimized to screen the largest possible volume of blood in the cubital vein. Therefore, the sensitivity for detecting circulating cells is far superior to exisiting in vitro methods that work with the limited volume of a blod sample.

Once the BMProbe is withdrawn, the number of isolated cells can be determined in just over an hour. This procedure is semi-automated and requires little training. Using the BMProbe, downstream molecular diagnostics are possible.

 

 

 

 

Circulating Endothelial Cells:  

Endothelial cells provide the physical interface between blood and surrounding tissue. They regulate nutrient and blood component traffic. Due to mechanical or chemical reactions endothelial cells can detach and enter the blood stream. They are then referred to as Circulating Endothelial Cells (CECs). CECs are low in healthy patients (around 4 CECs/mL) and increased in patient with Acute Conorary Artery Disease or Heart Failure patients, among others. CECs are therefore considered a biomarker to monitor arterial plaque disruption as well as treatment response.  

Circulating Tumor Cells: 

Circulating Tumor Cells (CTCs) represent a proven diagnostic and prognostic indicator of cancer progression. They disintegrate very early from the primary tumor and travel via the blood stream to all parts of the body. Isolating and analysing CTCs enables an earlier detection of the tumor than by using common imaging technology, resulting in a higher probability of successful treatment. Additionally, distant metastases that may even be present in early-stage patients, can be detected and identified. This can help physicians selecting the optimal treatment for each patient.

Team

Gaines Carter BS, JD.

Gaines Carter BS, JD.
Managing Director

Gabi Wendt

Gabi Wendt
Head of Quality and Regulatory Affairs

Klaus Lücke, Ph.D.

Klaus Lücke, Ph.D.
Business Developer

Nina Baar

Nina Baar
Head of R&D

Jan Orzel

Jan Orzel
Head of Production

Sara Campos, Ph.D.

Sara Campos, Ph.D.
Head of Diagnostic

Jasmin Preiß

Jasmin Preiß
Student Assistant

Alexander Quedenau

Alexander Quedenau
Student Assistant

Patrick Lücke

Patrick Lücke
Production Assistant

Ernst Wellnhofer, PD Dr. med

Ernst Wellnhofer, PD Dr. med
Consultant – Clinical Trial

/